ArticleDermatology practical & conceptual2026
Effectiveness of Biological Therapy in Psoriasis: Real-World Evaluation of SII and SIRI as Biomarkers of Systemic Inflammation.
Article in Dermatology practical & conceptual, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPsoriasis is a chronic inflammatory skin disease characterized by accelerated keratinocyte turnover and systemic inflammation mediated by an altered immune response. Biological drugs have significantly improved treatment outcomes in moderate to severe psoriasis. The Systemic Inflammation Response Index (SIRI) and the Systemic Immune-Inflammation Index (SII) have emerged as potential biomarkers for assessing systemic inflammation.
objectiveThe primary objective of this study was to assess changes in SIRI and SII over six and 12 months across different biological therapies (TNF-α, IL-17, IL-12/23, and IL-23 inhibitors) in patients with moderate-to-severe psoriasis. Secondary objectives included evaluating the impact of sex and comorbidities (obesity, metabolic syndrome, or psoriatic arthritis) on inflammatory markers reduction.
methodsA retrospective observational single-center study was conducted analyzing records from January 2010 to December 2024. Patients with moderate-to-severe psoriasis (PASI >10) and at least one comorbidity were included. The study excluded those with other chronic inflammatory diseases or immunosuppressive treatment.
resultsAmong 98 patients, TNF-α and IL-17 inhibitors showed the greatest SII reduction, while TNF-α and IL-12/23 inhibitors had the most significant SIRI reduction. Males exhibited a greater reduction in both indices. Among comorbidities, obesity was associated with the most pronounced decrease in inflammatory indices, followed by metabolic syndrome and psoriatic arthritis, which showed significant but less marked reductions.
conclusionsSII and SIRI may serve as valuable biomarkers for monitoring systemic inflammation in psoriasis patients undergoing biological therapy. Further studies are needed to validate their role in routine disease management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.